Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Advances in Drug Therapy for Systemic Lupus Erythematosus

Author(s): Xinghua Zhao, Jiaojiao Zhang, Yutong Liang, Jie Li, Shi Ding, Yang Wang, Ye Chen* and Ju Liu*

Volume 28, Issue 6, 2021

Published on: 25 June, 2020

Page: [1251 - 1268] Pages: 18

DOI: 10.2174/0929867327666200625150408

Price: $65

Abstract

Background: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by a local or systemic inflammatory response. At present, the increasing research results show that the pathogenesis of the disease is complex, and the methods of clinical treatment also show diversity. This review analyzes and summarizes the existing mechanism research and drug treatment methods in order to provide a reference value for further drug research and development.

Method: We carried out a thorough literature search using databases. According to the main purpose of the article, irrelevant articles were excluded after further examination and directly relevant articles were included. Finally, the information related to the article was summarized.

Result: In this article, seventy-four articles are included. According to related articles, there are mainly four kinds of drugs, namely antimalarial drugs, glucocorticoids, immunosuppressive agents and biological agents. About fifty-five articles summarized the drugs for the treatment of systemic lupus erythematosus. The rest of the articles were related to the research progress of the mechanism of systemic lupus erythematosus.

Conclusion: This article describes the pathogenesis of systemic lupus erythematosus, and summarizes the traditional and new therapeutic drugs, which is not only beneficial to the treatment of lupus erythematosus patients, but also plays a vital reference significance for the future development of new systemic lupus erythematosus drugs.

Keywords: Systemic lupus erythematosus, pathogenesis, therapeutic drugs, antimalarial drugs, glucocorticoid drugs, immunosuppressive agents, biological agents.

« Previous
[1]
Khattri, S.; Zandman-Goddard, G. Statins and autoimmunity. Immunol. Res., 2013, 56(2-3), 348-357.
[http://dx.doi.org/10.1007/s12026-013-8409-8] [PMID: 23572428]
[2]
Somers, E.C.; Marder, W.; Cagnoli, P.; Lewis, E.E.; DeGuire, P.; Gordon, C.; Helmick, C.G.; Wang, L.; Wing, J.J.; Dhar, J.P.; Leisen, J.; Shaltis, D.; McCune, W.J.; McCune, W.G. Population-based incidence and prevalence of systemic lupus erythematosus: the michigan lupus epidemiology and surveillance program. Arthritis Rheumatol., 2014, 66(2), 369-378.
[http://dx.doi.org/10.1002/art.38238] [PMID: 24504809]
[3]
Zhu, Q.; Wu, B.; Zhang, L.; Wang, Y.; Xie, C. The role of B cells in the pathogenesis of systemic lupus erythematosus. J. Qiqihar Med. Uni., 2019, 40(03), 351-354.
[4]
Meiqing, L.; Qilin, G.; Tao, S. The study of relativity between abnormal expression of cytokineTh1、Th2 which in systimic lupus erythematiosus patients and dysfunction of T cell subpopulation. Med. Lab. Sci. Clin., 2007, 2007(05), 4-6.
[5]
Lu, F.; Ji, H.; Sun, H.; Liu, B. Analysis on the correlation between the changes of T cell subset, IL-6, IL-18 and IFN-γ and the morbidity of systemic lupus erythematosus and on its possible pathogenesis. China Med. Equ., 2019, 16(03), 88-91.
[6]
Ramsköld, D.; Parodis, I.; Lakshmikanth, T.; Sippl, N.; Khademi, M.; Chen, Y.; Zickert, A.; Mikeš, J.; Achour, A.; Amara, K.; Piehl, F.; Brodin, P.; Gunnarsson, I.; Malmström, V. B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine, 2019, 40, 517-527.
[http://dx.doi.org/10.1016/j.ebiom.2018.12.035] [PMID: 30593436]
[7]
Chen, X.; Sun, X.; Yang, W.; Yang, B.; Zhao, X.; Chen, S.; He, L.; Chen, H.; Yang, C.; Xiao, L.; Chang, Z.; Guo, J.; He, J.; Zhang, F.; Zheng, F.; Hu, Z.; Yang, Z.; Lou, J.; Zheng, W.; Qi, H.; Xu, C.; Zhang, H.; Shan, H.; Zhou, X.J.; Wang, Q.; Shi, Y.; Lai, L.; Li, Z.; Liu, W. An autoimmune disease variant of IgG1 modulates B cell activation and differentiation. Science, 2018, 362(6415), 700-705.
[http://dx.doi.org/10.1126/science.aap9310] [PMID: 30287618]
[8]
Mahto, H.; Tripathy, R.; Meher, B.R.; Prusty, B.K.; Sharma, M.; Deogharia, D.; Saha, A.K.; Panda, A.K.; Das, B.K. TNF-α promoter polymorphisms (G-238A and G-308A) are associated with susceptibility to systemic lupus erythematosus (SLE) and P. falciparum malaria: a study in malaria endemic area. Sci. Rep., 2019, 9(1), 11752.
[http://dx.doi.org/10.1038/s41598-019-48182-5] [PMID: 31409832]
[9]
Rönnblom, L.; Alm, G.V. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol., 2001, 22(8), 427-431.
[http://dx.doi.org/10.1016/S1471-4906(01)01955-X] [PMID: 11473831]
[10]
I-Tsu. C.; Tzeng, H.; Chen, J. Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus. Cells, 2019, 8(9), 963.
[http://dx.doi.org/10.3390/cells8090963] [PMID: 31450787]
[11]
Karampetsou, M.P.; Comte, D.; Suárez-Fueyo, A.; Katsuyama, E.; Yoshida, N.; Kono, M.; Kyttaris, V.C.; Tsokos, G.C. SLAMF1 engagement inhibits T cell-B cell interaction and diminishes IL-6 production and plasmablast differentiation in systemic lupus erythematosus. Arthritis Rheumatol., 2019, 71(1), 99-108.
[http://dx.doi.org/10.1002/art.40682]] [PMID: 30058241]
[12]
Qiao, Y.; Wang, J.; Liang, Z.; Jing, X.; Hao, M.; Chen, J. Effects of regulatory B cells on CD4~+ T cell subsets in systemic lupus erythematosus. Zhonghua Linchuang Yishi Zazhi, 2017, 11(07), 1208-1211.
[13]
Zumaquero, E.; Stone, S.L.; Scharer, C.D.; Jenks, S.A.; Nellore, A.; Mousseau, B.; Rosal-Vela, A.; Botta, D.; Bradley, J.E.; Wojciechowski, W.; Ptacek, T.; Danila, M.I.; Edberg, J.C.; Bridges, S.L. Jr.; Kimberly, R.P.; Chatham, W.W.; Schoeb, T.R.; Rosenberg, A.F.; Boss, J.M.; Sanz, I.; Lund, F.E. IFNγ induces epigenetic programming of human T-bethi B cells and promotes TLR7/8 and IL-21 induced differentiation. eLife, 2019, 8e41641
[http://dx.doi.org/10.7554/eLife.41641] [PMID: 31090539]
[14]
Li, S.; Xiao, W. Research progress of chemokine CXCL13 in systemic lupus erythematosus. Chin. J. Immunol., 2019, 35(12), 1528-1532.
[15]
Luo, B.; Zeng, H.; Zhang, Y.; Ye, Z. Research progress of long-chain non-coding RNA in systemic lupus erythematosus. Rheumat. Arthritis, 2019, 8(08), 68-72.
[16]
Ding, S.; Zhang, Q.; Luo, S. Gao. L.;Huang, J.;Lu, J.;Chen, J.;Zeng, Q.;Guo, A.;Zeng, J.;Lu, Q. BCL-6 suppresses miR-142-3p/5p expression in SLE CD4+ T cells by modulating histone methylation and acetylation of the miR-142 promoter. Cell. Mol. Immunol., 2019, 17(5), 474-482.
[http://dx.doi.org/10.1038/s41423-019-0268-3]] [PMID: 31431691]
[17]
Qian, T.; Yang, Y.; Qianjin, L. Research progress on microRNAs’ role in the pathogenesis of systemic lupus erythematosus. J. Prac. Derma., 2014, 7(05), 367-369.
[18]
Dong, Y.; Wang, S.; Liu, H. Current situation and progress of application of hydroxychloroquine and its blood concentration in the treatment of systemic lupus erythematosus. Med. Recapitulate, 2018, 24(15), 3039-3044.
[19]
Li, W.D.; Dong, Y.J.; Tu, Y.Y.; Lin, Z.B. Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation. Int. Immunopharmacol., 2006, 6(8), 1243-1250.
[http://dx.doi.org/10.1016/j.intimp.2006.03.004] [PMID: 16782536]
[20]
Yang, L.; Zhang, D. Summary of dihydroartemisinin and its application for the treatment of lupus erythematosus. Chin. Sci. Bull., 2017, 62(18), 2007-2012.
[http://dx.doi.org/10.1360/N972017-00172]
[21]
Zuo, Y.; Jin, H. Expert consensus on the treatment of immune-related dermatosis with glucocorticoid. Chin. J. Allergy Clin. Immunol., 2018, 12(01), 1-7.
[22]
Deng, J.; Chalhoub, N.E.; Sherwin, C.M.; Li, C.; Brunner, H.I. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Semin. Arthritis Rheum., 2019, 49(2), 251-259.
[http://dx.doi.org/10.1016/j.semarthrit.2019.03.010] [PMID: 30987856]
[23]
Tang, J.; Zheng, X. Investigation of the effects of dexamethasone on STAT1 in monocytes of patients with SLE. Chin. J. Microbiol. Immunol., 2004, (07), 26-29.
[24]
Huang, Y.; Zhang, Y.; Tao, J. Updates on application and clinical research of glucocorticoids in the treatment of systemic lupus erythematosus. Derma. Bulletin, 2018, 35(03), 296-304 + 238,,
[25]
Yang, D. Clinical research of low-dosage hormone combined with cyclophosphamide in the treatment of systemic lupus erythematosus. J. Snake, 2019, 31(02), 213-214.
[26]
Liu, J.; Luo, D. Prevention and side effects of the medication treatment for systemic lupus erythematosus. Derma. Bulletin, 2018, 35(03), 328-334+241,
[27]
Yang, Q. Commonly used immunosuppressive agents and their immunosuppressive mechanism. Biol. Teach., 2019, 44(07), 2-3.
[28]
Li, Q.; Zhang, K.; Lao, M.; Lian, S.; Liu, K. Efficacy and safety of methotrexate treatment of systemic lupus erythematosus. Jilin Med. J., 2014, 35(13), 2762-2765.
[29]
Yan, T. Analysis of the research progress of biotechnology drugs in the treatment of systemic lupus erythematosus. Chin. Comm. Doc., 2017, 33(01), 6-7.
[30]
Lourdudoss, C.; Vollenhoven, Rv. Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center. Lupus, 2014, 23(3), 299-304.
[http://dx.doi.org/10.1177/0961203313519158] [PMID: 24399811]
[31]
Kim, C.; Kim, E. Rational drug design approach of receptor tyrosine kinase type III inhibitors. Curr. Med. Chem., 2019, 26(42), 7623-7640.
[http://dx.doi.org/10.2174/0929867325666180622143548] [PMID: 29932031]
[32]
Olgen, S. Overview on anticancer drug design and development. Curr. Med. Chem., 2018, 25(15), 1704-1719.
[http://dx.doi.org/10.2174/0929867325666171129215610] [PMID: 29189124]
[33]
de Azevedo, W.F. Jr Molecular dynamics simulations of protein targets identified in Mycobacterium tuberculosis. Curr. Med. Chem., 2011, 18(9), 1353-1366.
[http://dx.doi.org/10.2174/092986711795029519] [PMID: 21366529]
[34]
Canduri, F.; Perez, P.C.; Caceres, R.A.; de Azevedo, W.F., Jr Protein kinases as targets for antiparasitic chemotherapy drugs. Curr. Drug Targets, 2007, 8(3), 389-398.
[http://dx.doi.org/10.2174/138945007780058979] [PMID: 17348832]
[35]
Wu, W.; Tao, D.; Zhang, R. Curative efficacy of leflunomide in treatment of systemic lupus erythematosus and effects on serum BAFF MCP-4 IL-8 and IL-10 levels. Hebei Med., 2018, 24(12), 1957-1960.
[36]
Ren, Y.; Luo, Y. A new immunomodulator: leflunomide. Chi. J. Drugs Clin. Rem., 2004, 2004(07), 451-454.
[37]
Zhou, X. The efficacy of mycophenolate mofetil (MMF) combined with prednisone in the treatment of chronic glomerulonephritis. Contemp. Med., 2019, 25(28), 185-186.
[38]
Liu, C.; Ge, X.G.; Hao, Q.X.; Guo, L.P.; Yuan, Q.J.; Huang, L.Q. Investigation report of Tripterygium wilfordii and Tripterygium hypoglaucum. Zhong Yao Cai, 2015, 38(2), 249-253.
[PMID: 26415397]
[39]
Feng, Y.; Li, D.; Li, X. Efficacy of mycophenolate mofetil in the treatment of systemic lupus erythematosus and its influence on immune function. Hainan Med. J., 2018, 29(23), 3280-3282.
[40]
Tang, B. Clinical effect analysis of hormone combined with cyclophosphamide in the treatment of systemic lupus erythematosus nephritis. Sys. Med., 2018, 3(19), 47-49.
[41]
Xie, W.; Zhang, Z. Research status of therapeutic drug monitoring in systemic lupus erythematosus. Zhongguo Lin Chuang Yao Li Xue Za Zhi, 2019, 35(01), 87-90.
[42]
Wu, Y. The effects of SM934 a water-soluble artemisinin derivative, on the treatment of systemic lupus erythematosus; Shanghai Institute of Materia Medica, 2016.
[43]
Gordon, C.; Bassi, R.; Chang, P.; Kao, A.; Jayne, D.; Wofsy, D.; Fleuranceau-Morel, P. Integrated safety profile of atacicept: An analysis of pooled data from the atacicept clinical trial programme. Rheumatol. Adv. Pract., 2019, 3(2)rkz021
[http://dx.doi.org/10.1093/rap/rkz021]] [PMID: 31528843]
[44]
Finck, B.K.; Linsley, P.S.; Wofsy, D. Treatment of murine lupus with CTLA4Ig. Science, 1994, 265(5176), 1225-1227.
[http://dx.doi.org/10.1126/science.7520604] [PMID: 7520604]
[45]
Merrill, J.T.; Burgos-Vargas, R.; Westhovens, R.; Chalmers, A.; D’Cruz, D.; Wallace, D.J.; Bae, S.C.; Sigal, L.; Becker, J.C.; Kelly, S.; Raghupathi, K.; Li, T.; Peng, Y.; Kinaszczuk, M.; Nash, P. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum., 2010, 62(10), 3077-3087.
[http://dx.doi.org/10.1002/art.27601] [PMID: 20533545]
[46]
Wang, L.; Cheng, H.; Li, D.; Li, B.; Lyu, L. Advances in biological treatments for systemic lupus erythematosus. Prog. Pharma. Sci., 2018, 42(10), 744-753.
[47]
Du, Y.; Du, L.; He, Z.; Zhou, J.; Wen, C.; Zhang, Y. Cryptotanshinone ameliorates the pathogenesis of systemic lupus erythematosus by blocking T cell proliferation. Int. Immunopharmacol., 2019, 74105677
[http://dx.doi.org/10.1016/j.intimp.2019.105677] [PMID: 31177018]
[48]
Li, J.; Wei, M.M.; Song, Q.; Guo, X.H.; Shao, L.; Liu, Y. Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials. Exp. Ther. Med., 2019, 18(2), 1500-1506.
[http://dx.doi.org/10.3892/etm.2019.7630] [PMID: 31316634]
[49]
Geh, D.; Gordon, C. Epratuzumab for the treatment of systemic lupus erythematosus. Expert Rev. Clin. Immunol., 2018, 14(4), 245-258.
[http://dx.doi.org/10.1080/1744666X.2018.1450141] [PMID: 29542345]
[50]
Fleischer, V.; Sieber, J.; Fleischer, S.J.; Shock, A.; Heine, G.; Daridon, C.; Dörner, T. Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients. Arthritis Res. Ther., 2015, 17(32), 185.
[http://dx.doi.org/10.1186/s13075-015-0686-2] [PMID: 26183319]
[51]
Clowse, M.E.; Wallace, D.J.; Furie, R.A.; Petri, M.A.; Pike, M.C.; Leszczyński, P.; Neuwelt, C.M.; Hobbs, K.; Keiserman, M.; Duca, L.; Kalunian, K.C.; Galateanu, C.; Bongardt, S.; Stach, C.; Beaudot, C.; Kilgallen, B.; Gordon, C. EMBODY Investigator Group. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol., 2017, 69(2), 362-375.
[http://dx.doi.org/10.1002/art.39856] [PMID: 27598855]
[52]
Dennis, G.J. Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus. Clin. Pharmacol. Ther., 2012, 91(1), 143-149.
[http://dx.doi.org/10.1038/clpt.2011.290] [PMID: 22130121]
[53]
Furie, R.; Petri, M.; Zamani, O.; Cervera, R.; Wallace, D.J.; Tegzová, D.; Sanchez-Guerrero, J.; Schwarting, A.; Merrill, J.T.; Chatham, W.W.; Stohl, W.; Ginzler, E.M.; Hough, D.R.; Zhong, Z.J.; Freimuth, W.; van Vollenhoven, R.F. BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum., 2011, 63(12), 3918-3930.
[http://dx.doi.org/10.1002/art.30613] [PMID: 22127708]
[54]
Hsu, H.; Khare, S.D.; Lee, F.; Miner, K.; Hu, Y.L.; Stolina, M.; Hawkins, N.; Chen, Q.; Ho, S.Y.; Min, H.; Xiong, F.; Boone, T.; Zack, D.J. A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease. Clin. Exp. Rheumatol., 2012, 30(2), 197-201.
[PMID: 22325420]
[55]
Merrill, J.T.; Shanahan, W.R.; Scheinberg, M.; Kalunian, K.C.; Wofsy, D.; Martin, R.S. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis., 2018, 77(6), 883-889.
[http://dx.doi.org/10.1136/annrheumdis-2018-213032] [PMID: 29563108]
[56]
Ginzler, E.M.; Wax, S.; Rajeswaran, A.; Copt, S.; Hillson, J.; Ramos, E.; Singer, N.G. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res. Ther., 2012, 14(1), R33-R33.
[http://dx.doi.org/10.1186/ar3738] [PMID: 22325903]
[57]
Merrill, J.T.; Wallace, D.J.; Wax, S.; Kao, A.; Fraser, P.A.; Chang, P.; Isenberg, D. ADDRESS II Investigators. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol., 2018, 70(2), 266-276.
[http://dx.doi.org/10.1002/art.40360] [PMID: 29073347]
[58]
Volkart, P.A.; Bitencourt-Ferreira, G.; Souto, A.A.; de Azevedo, W.F. Cyclin-dependent kinase 2 in cellular senescence and cancer. a structural and functional review. Curr. Drug Targets, 2019, 20(7), 716-726.
[http://dx.doi.org/10.2174/1389450120666181204165344] [PMID: 30516105]
[59]
de Azevedo, W.F. Jr. Opinion paper: targeting multiple cyclin-dependent kinases (CDKS): a new strategy for molecular docking studies. Curr. Drug Targets, 2016, 17(1), 2.
[http://dx.doi.org/10.2174/138945011701151217100907] [PMID: 26687602]
[60]
Canduri, F.; Silva, R.G.; dos Santos, D.M.; Palma, M.S.; Basso, L.A.; Santos, D.S.; de Azevedo, W.F. Jr. Structure of human PNP complexed with ligands. Acta Crystallogr. D Biol. Crystallogr., 2005, 61(Pt 7), 856-862.
[http://dx.doi.org/10.1107/S0907444905005421] [PMID: 15983407]
[61]
Canduri, F.; Fadel, V.; Basso, L.A.; Palma, M.S.; Santos, D.S.; de Azevedo, W.F. Jr. New catalytic mechanism for human purine nucleoside phosphorylase. Biochem. Biophys. Res. Commun., 2005, 327(3), 646-649.
[http://dx.doi.org/10.1016/j.bbrc.2004.12.052] [PMID: 15649395]
[62]
Filgueira de Azevedo, W., Jr; Canduri, F.; Simões de Oliveira, J.; Basso, L.A.; Palma, M.S.; Pereira, J.H.; Santos, D.S. Molecular model of shikimate kinase from Mycobacterium tuberculosis. Biochem. Biophys. Res. Commun., 2002, 295(1), 142-148.
[http://dx.doi.org/10.1016/S0006-291X(02)00632-0] [PMID: 12083781]
[63]
Petri, M.; Wallace, D.J.; Spindler, A.; Chindalore, V.; Kalunian, K.; Mysler, E.; Neuwelt, C.M.; Robbie, G.; White, W.I.; Higgs, B.W.; Yao, Y.; Wang, L.; Ethgen, D.; Greth, W. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum., 2013, 65(4), 1011-1021.
[http://dx.doi.org/10.1002/art.37824] [PMID: 23400715]
[64]
Takeuchi, T.; Tanaka, Y.; Matsumura, R.; Saito, K.; Yoshimura, M.; Amano, K.; Atsumi, T.; Suematsu, E.; Hayashi, N.; Wang, L.; Tummala, R. Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: a multicentre, phase 2, open-label study. Mod. Rheumatol., 2020, 30(1), 93-100.
[http://dx.doi.org/10.1080/14397595.2019.1583832]] [PMID: 30791804]
[65]
Khamashta, M.; Merrill, J.T.; Werth, V.P.; Furie, R.; Kalunian, K.; Illei, G.G.; Drappa, J.; Wang, L.; Greth, W. CD1067 study investigators. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis., 2016, 75(11), 1909-1916.
[http://dx.doi.org/10.1136/annrheumdis-2015-208562] [PMID: 27009916]
[66]
Fautrel, B.; Kirkham, B.; Pope, J.E.; Takeuchi, T.; Gaich, C.; Quebe, A.; Zhu, B.; de la Torre, I.; De Leonardis, F.; Taylor, P.C. Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM. J. Clin. Med., 2019, 8(9)E1394
[http://dx.doi.org/10.3390/jcm8091394] [PMID: 31492040]
[67]
Wallace, D.J.; Furie, R.A.; Tanaka, Y.; Kalunian, K.C.; Mosca, M.; Petri, M.A.; Dörner, T.; Cardiel, M.H.; Bruce, I.N.; Gomez, E.; Carmack, T.; DeLozier, A.M.; Janes, J.M.; Linnik, M.D.; de Bono, S.; Silk, M.E.; Hoffman, R.W. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet, 2018, 392(10143), 222-231.
[http://dx.doi.org/10.1016/S0140-6736(18)31363-1] [PMID: 30043749]
[68]
Riggs, J.M.; Hanna, R.N.; Rajan, B.; Zerrouki, K.; Karnell, J.L.; Sagar, D.; Vainshtein, I.; Farmer, E.; Rosenthal, K.; Morehouse, C.; de Los Reyes, M.; Schifferli, K.; Liang, M.; Sanjuan, M.A.; Sims, G.P.; Kolbeck, R. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci. Med., 2018, 5(1)e000261
[http://dx.doi.org/10.1136/lupus-2018-000261] [PMID: 29644082]
[69]
Felten, R.; Scher, F.; Sagez, F.; Chasset, F.; Arnaud, L. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des. Devel. Ther., 2019, 13, 1535-1543.
[http://dx.doi.org/10.2147/DDDT.S170969] [PMID: 31190735]
[70]
Furie, R.; Khamashta, M.; Merrill, J.T.; Werth, V.P.; Kalunian, K.; Brohawn, P.; Illei, G.G.; Drappa, J.; Wang, L.; Yoo, S. CD1013 study investigators. anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol., 2017, 69(2), 376-386.
[http://dx.doi.org/10.1002/art.39962] [PMID: 28130918]
[71]
Lovero, R.; Losurdo, G.; Mastromauro, M.; Castellaneta, N.M.; Mongelli, A.; Gentile, A.; Di Leo, A.; Principi, M. A case of severe transaminase elevation following a single ustekinumab dose with remission after drug withdrawal. Curr. Drug Saf., 2018, 13(3), 221-223.
[http://dx.doi.org/10.2174/1574886313666180719165212] [PMID: 30027852]
[72]
van Vollenhoven, R.F.; Hahn, B.H.; Tsokos, G.C.; Wagner, C.L.; Lipsky, P.; Touma, Z.; Werth, V.P.; Gordon, R.M.; Zhou, B.; Hsu, B.; Chevrier, M.; Triebel, M.; Jordan, J.L.; Rose, S. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet, 2018, 392(10155), 1330-1339.
[http://dx.doi.org/10.1016/S0140-6736(18)32167-6] [PMID: 30249507]
[73]
Costedoat-Chalumeau, N.; Houssiau, F.A. Ustekinumab: a promising new drug for SLE? Lancet, 2018, 392(10155), 1284-1286.
[http://dx.doi.org/10.1016/S0140-6736(18)32330-4] [PMID: 30249508]
[74]
Ma, H.; Liu, C.; Shi, B.; Zhang, Z.; Feng, R.; Guo, M.; Lu, L.; Shi, S.; Gao, X.; Chen, W.; Sun, L. Mesenchymal stem cells control complement C5 activation by factor H in lupus nephritis. EBioMedicine, 2018, 32, 21-30.
[http://dx.doi.org/10.1016/j.ebiom.2018.05.034] [PMID: 29885865]
[75]
Wozniacka, A.; Lesiak, A.; Boncela, J.; Smolarczyk, K.; McCauliffe, D.P.; Sysa-Jedrzejowska, A. The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br. J. Dermatol., 2008, 159(5), 1124-1130.
[http://dx.doi.org/10.1111/j.1365-2133.2008.08804.x] [PMID: 18764842]
[76]
Li, Y.; Zuo, J.; Yang, Z.; Zhou, W.; Sui, Y.; Wang, J.; Zhang, Y.; Zhou, Y.; Wu, J. Artemisinin (qinghaosu) derivatives, their preparation methods and their use, and pharmaceutical compositions containing the same. US Patent US7910750B2, January 27 2006

Rights & Permissions Print Cite
Article Metrics
89
1
World Chagas Disease
© 2024 Bentham Science Publishers | Privacy Policy